• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Increased Risk of Myocardial Ischemia and Death in Severely Anemic Patients who Decline Transfusions

October 10, 2018

Increased cardiac output can aid oxygen delivery in patients with mild anemia. When a critical hemoglobin (Hb) concentration is reached and oxygen delivery is at capacity, more severe anemia can lead to tissue ischemia, organ failure, myocardial infarction, and even death.  Little data on the critical hemoglobin threshold is available for patients with comorbidities.  In order to investigate the critical hemoglobin concentration in severely anemic patients, researchers conducted a retrospective chart review of registered patients at Duke University Medical Center who refused blood products over a ten-year period.  Among 263 hospitalized patients with severe anemia (nadir Hb of 8 g/dL or less), the odds of mortality increased by 55% per 1 g/dL decrease of the nadir Hb (OR, 1.55 [95% CI, 1.25-1.91]; p<0.0001).  The risk of myocardial ischemia also increased with decreasing nadir Hb.  Untreated severe anemia can become life-threatening, and alternative treatment options could be beneficial for patients who decline transfusions.

Reference:

  1. Guinn NR, Cooter ML, Villalpando C, and RB Weiskopf. Severe anemia associated with increased risk of death and myocardial ischemia in patients declining blood transfusion. Transfusion 2018; 58; 2290-2296.  

Filed Under

  • CME
  • News
  • RBC Transfusion

Recommended

  • FDA Issues Emergency Use Authorization for SARS-CoV-2 Monoclonal Antibody Therapy

  • Transfusion Guidelines for Major Hemorrhage

  • Blood Transfusions Reduce Mortality in Patients with Sickle Cell Anemia

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Impact of Individual Donor Assessment Deferral Changes on Donor HIV, HBV, HCV, and Syphilis Prevalence

  • RBC Transfusions in Neonatal ICUs Above Restrictive Hb Thresholds

  • Locally Transmitted Malaria in the United States

  • Global Platelet Transfusion Practices for Patients in the ICU

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley